+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB
Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

News U1

07 Jun

NANOLIGENT, the first drug designed to eliminate metastases stem cells

NANBIOSIS researchers have developed a nanomedicine for the treatment of metastases by the selective elimination of tumor stem cells. It is a system based on nanoparticles that transport a chemotherapeutic drug and release it into cancer cells. The research team, led by Esther Vázquez and Antonio Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP), in the IBB-UAB, and Ramon Mangues, Scientific Director of NANBIOSIS U18. Nanotoxicology Unit, in the Sant Pau Hospital, have already created a prototype of the drug and have conducted in vivo trials in animal models of colorectal cancer. They have demonstrated their effectiveness, selectiv[...]

25 May

Prof. A. Villaverde interviewed by CIBER-BBN Bulletin

Prof. Antoni Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP), in an interview for the CIBER-BBN Bulletin, speaks about his research group, coordinanting NANBIOSIS u1 and the benefits of belonging to a research structure like CIBER. “The PPP – explains Prof. Villaverde – was generated within the group, but is currently a platform that has been gaining its own entity and structure, and has received the ISO certification granted by AENOR. Neus Ferrer-Miralles is the Scientific Director and Paolo Saccardo the technical coordinator. The objective of the activity developed by the PPP is based on supporting CIBER groups in the production and[...]

11 May

Fabry disease awareness month, April

The Fabry International Network (FIN) association established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry Disease is one of several dozen Lysosomal Storage Disorders that interfere with the body’s ability to break down specific fatty substances. It is a rare disease and because the rate of occurrence is less than 1 in 200,000, it is considered as one of the many “Orphan” diseases. It is more common in women, but it occurs with greater severity in men. Fabry disease is a metabolic[...]

26 Apr

Designing nanomedicines

Next May 3, will take place in Barcelona, at the Academy of Medical and Health Sciences of Catalonia and the Balearic Island, an informative session and debate about Nanotecnology and Health “Designing Nanomedicines” in wich Prof. Antonio Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP) will give a talk on “Nanobiotechnological approaches to cancer medicine“. Prof. Jesús Martínez de la Fuente, (ICMAB-CSIC / Universidad de Zaragoza – CIBER-BBN) will speak about “the nanorevolution: towards a healthier world“. The organization of the even has been in charge of Pilar Marco, Scientific Director of NANBIOSIS U2  Custom Antibody Service (CAbS), as a member[...]

25 Apr

Communication in science and transfer with Professor Antoni Villaverde

On June 6th, Aula Científica, in collaboration with IBB, organizes a theoretical and practical course on “Principles and practice of communication in science and in transfer“. Professor Antoni Villaverde, Strategy Director of NANBIOSIS U1. Protein Production Platform (PPP), will transmit his knowledge and experience on the preparation of scientific articles. The objectives of the course, aimed at researchers, entrepreneurs, teachers and managers of research and transfer, are to offer basic conceptual and instrumental tools in scientific communication, focused on the writing of scientific manuscripts, preparation of scientific and technological innovation projects and transfer , and in oral and corporal expression during[...]

28 Feb

“Smart-4-Fabry”: European project focused on the Fabry rare disease, participated by 4 units of NANBIOSIS

Smart-4-Fabry is a project coordinated by CIBER-BBN, funded by the European Commission within the Horizon 2020 Research and Innovation program with € 5.8 M for 4 years, which aims to develop a new nanomedicine for the treatment of the Fabry rare disease.   Fabry disease is a rare disease belonging to the group of lysosomal storage disorders, with a global incidence of 1:5,000 – 1:10,000, representing a priority health problem at European level.   The European project “Smart-4-Fabry”, is coordinated by CIBER-BBN, specifically by NANOMOL group at ICMAB-CSIC (Dr. Nora Ventosa) and the Biomaterial Processing and Nanostructuring Unit (U6) of  ICTS “NANBIOSIS”, and it[...]

11 Jan

Improving biomaterials imaging for nanotechnology: rapid methods for protein localization at ultrastructural level

New publication of Tony Villaverde, Scientific Director of Unit 1 of NANBIOSIS acepted by Biotechnology Journal: The preparation of biological samples for electron microscopy is material- and time-consuming because it is often based on long protocols that also may produce artifacts. Protein labeling for transmission electron microscopy (TEM) is such an example, taking several days. However, for protein-based nanotechnology, high resolution imaging techniques are unique and crucial tools for studying the spatial distribution of these molecules, either alone or as components of biomaterials. In this paper, we tested 2 new short methods of immunolocalization for TEM, and compared them with a[...]

20 Nov

Intracellular trafficking of a dynein-based nanoparticle designed for gene delivery

Unit 1 of NANBIOSIS, Protein Production Platform (PPP) and the  Nanobiotechnology research group of CIBER-BBN in collaboration with the Universidade Estadual de Campinas and the Universidade de São Paulo have recently published, in the European Journal of Pharmaceutical Sciences, the results of the research devoted to the improvement of protein-only based nanoconjugates for gene therapy. The evaluated gene-therapy vehicle prototype  displayed a similar transfection efficiency to that of the commercial vector LipofectamineTM 2000. Article of reference: https://doi.org/10.1016/j.ejps.2017.11.002[...]

U1-Protein Production Platform - PPP
Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo mroyo@pcb.ub.cat
  • Entities: Parc Cientific de Barcelona (PCB) & Universidad de Barcelona (UB)
  • Address: Baldiri Reixac 10, 08028, Barcelona, Spain
  • Phone: +34 934 037 122
  • Web:PCB – UB

PCB

Order request

Description

This Unit is coordinated by the Peptides and Nanoparticles Group at the Parc Científic de Barcelona (PCB) and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the PCB with an occupy area of 5.000m2.

News U3

05 Jun

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds. Also CSIC (The State Agency Superior Council of[...]

11 May

Fabry disease awareness month, April

The Fabry International Network (FIN) association established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry Disease is one of several dozen Lysosomal Storage Disorders that interfere with the body’s ability to break down specific fatty substances. It is a rare disease and because the rate of occurrence is less than 1 in 200,000, it is considered as one of the many “Orphan” diseases. It is more common in women, but it occurs with greater severity in men. Fabry disease is a metabolic[...]

28 Feb

“Smart-4-Fabry”: European project focused on the Fabry rare disease, participated by 4 units of NANBIOSIS

Smart-4-Fabry is a project coordinated by CIBER-BBN, funded by the European Commission within the Horizon 2020 Research and Innovation program with € 5.8 M for 4 years, which aims to develop a new nanomedicine for the treatment of the Fabry rare disease.   Fabry disease is a rare disease belonging to the group of lysosomal storage disorders, with a global incidence of 1:5,000 – 1:10,000, representing a priority health problem at European level.   The European project “Smart-4-Fabry”, is coordinated by CIBER-BBN, specifically by NANOMOL group at ICMAB-CSIC (Dr. Nora Ventosa) and the Biomaterial Processing and Nanostructuring Unit (U6) of  ICTS “NANBIOSIS”, and it[...]

01 Feb

Microfluidic device that reproduces the blood-retinal barrier

The use of In vitro testing with living cells as an alternative to animal research has limitations like the difficulty to reproduce the interaction of cells. To overcome it, scientists are working on the development of systems that simulate and reproduce functions of tissues and organs in conditions very similar to reality. They are called organ-on-a-chip, which include microenvironments and microarchitectures that simulate the state of tissues and living organs. Scientists of NANBIOSIS Unit 8 have published in an article, cover of the magazine “Lab on a Chip”, the “proof of concept” of a microfluidic device that reproduces the blood-retinal barrier,[...]

22 Jan

Researchers of NANBIOSIS U3 find activators of a possible therapeutic target for the treatment of patients with diabetes and insulin resistance

Researchers of  NANBIOSIS U3: Synthesis of Peptides Unit participate in the identification of activators of of the mitochondrial protein Mitofusin 2, a possible therapeutic target for the treatment of patients with type 2 diabetes in collaboration with CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) and the CIBER of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Those researchers are led by Fernando Albericio (Scientific Director of Unit 3 of NANBIOSIS) at the University of Barcelona and Antonio Zorzano en el IRB Barcelona  have identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes. This protein is expressed[...]

16 Nov

Posters presentation by NANBIOSIS Units in CIBER-BBN ANNUAL CONFERENCE 2017

Last 13 and 14 of November, CIBER-BBN  has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and  Paolo Saccardo as Coordinator (in the picture): Posters: U1. Protein Production Platform (PPP): Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José[...]

28 Jun

“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”
“a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration”

Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo,  P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]

U3-Synthesis of Peptides Unit
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

  • Scientific Coordinator: Dr. Nathaly Segovia nvsegovia@icmab.es
  • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
  • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
  • Phone: +34 935 801 853
  • Fax: +34 935 805 729
  • Web: ICMAB
ICMAB CSIC
Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure.

One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.

 
U6. Services & Rates

News U6

12 Jun

New laboratory for unit 6 of NANBIOSIS

The equipment of NANBIOSIS U6-Processing of biomaterials and nanoestructuring, that at present are in several laboratories of the ICMAB-CSIC, are going to be transferred to their definitive location in the new laboratory of this NANBIOSIS unit. Given the large amount of equipment the process is expected to last two years, and itwill be done sequentially to continue to provide service to laboratory users. In this process, an engineer has been hired to play a key role, since he will not only be in charge of the transfer, but also to ensure the correct installation of equipment after its transfer and[...]

05 Jun

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds. Also CSIC (The State Agency Superior Council of[...]

22 May

Carbon-gold bonds for robusts molecule-electrode junctions

Marta Mas-Torrent, Jaume Veciana, and Nuria Crivillers, scientists of the research group NANOMOL, coordinating NANBIOSIS U6. Biomaterial Processing and Nanostructuring Unit, are co-authors of the article “Carbon-gold bonds for robusts molecule-electrode junctions” by  Journal of the American Chemical Society -JACS-. The researchers have studied the behaviour of an organic radical as a molecular wire formed by a covalent carbon-gold bond between the molecule and two electrodes. The molecule-metal junction is more stable and gemotrically better defined than its predecessors, in which other functional groups were used. This improvement opens up new horizons in the fabrication of novel electronic devices with applications[...]

21 May

Mesenchymal stem cells or exosomes with fibrin glue mesh fixation modulates the inflammatory reaction in a murine model of incisional hernia

Javier García Casado, Scientific Director of NANBIOSIS U14, Cell Therapy Unit, and Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU, are co-author of the publication “Fibrin glue mesh fixation combined with mesenchymal stem cells or exosomes modulates the inflammatory reaction in a murine model of incisional hernia” by Acta Biomaterialia. In vitro experiments were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Exosomes characterization was performed by the ICTS Nanbiosis (Unit 6: Biomaterial processing and Nanostructuring Unit). In vivo experiments were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). The study has demonstrated a[...]

11 May

Fabry disease awareness month, April

The Fabry International Network (FIN) association established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry Disease is one of several dozen Lysosomal Storage Disorders that interfere with the body’s ability to break down specific fatty substances. It is a rare disease and because the rate of occurrence is less than 1 in 200,000, it is considered as one of the many “Orphan” diseases. It is more common in women, but it occurs with greater severity in men. Fabry disease is a metabolic[...]

02 May

Nora Ventosa, Scientific Director of NANBIOSIS U6, presented the Smart4Fabry project to the compressed fluids community

Last  25th April, Nora Ventosa, Scientific Director of NANBIOSIS U6. Biomaterial Processing and Nanostructuring Unit, presented Smart4Fabry project to the compressed fluids community at the 12th International Symposium on Supercritical Fluids in Antibes, France. This event is held every three years, gathering investigators from all domains with the aim to promote knowledge and applications of Supercritical Fluids. According to the ISASF, International Society for Advancement of Supercritical Fluids, “a fluid is called “supercritical” when both its pressure and temperature are over its critical pressure and temperature. It is monophasic and exhibits specific properties, different from those of liquids and gases. Supercritical fluids have a hig[...]

23 Apr

Robust Organic Radical Molecular Junctions Using Acetylene Terminated Groups for C–Au Bond Formation

Jaume Veciana, Scientific Director of NANBIOSIS is co-author of the publication “Robust Organic Radical Molecular Junctions Using Acetylene Terminated Groups for C–Au Bond Formation” by “Journal of the American Chemical Society”. For further information: DOI: 10.1021/jacs.7b10019  J. Am. Chem. Soc., 2018, 140 (5), pp 1691–1696[...]

20 Apr

Two Units of NANBIOSIS participates in the CIBERONC – CIBER-BBN collaboratives projects

Scientists from two NANBIOSIS units participate in two of the three projects selected in the Call CIBER-BBN / CIBERONC. On April 13, the 1st CIBERONC – CIBER-BBN Collaborative Projects Forum took place at the National School of Health (Carlos III Health Institute). The purpose of the event was to carry out the resolution of the call for collaborative seed projects between the two areas. During the forum, 12 proposals for collaborative projects were presented, encompassed in four thematic sessions: new nano-devices, new strategies for 3D culture, phototherapy and drug release. All the proposals included the application of some of t[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

  • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
  • Scientific Coordinator: Dr. Jesús Ciriza Astrain jeciriza@gmail.com
  • Entities: Universidad del País Vasco (UPV/EHU)
  • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
  • Phone: +34 945 013091
  • Fax: +34 945 013040
  • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

News U10

20 Jun

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters.  The project, Position-II  (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), [...]

03 Jun

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers. The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of [...]

28 May

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with [...]

15 May

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, [...]

05 May

Gene therapy in pseudohypoparathyroidism

In 1942, Albright and colleagues described the first hormone resistance syndrome, which they called pseudohypoparathyroidism (PHP) (1), patients had a specific phenotype consisting of short stature, central obesity, round face, short neck and brachydactyly, which is what that today we know like Albright Hereditary Osteodystrophy (AHO, Albright Hereditary Osteodystrophy). Nanobiocel research group, coordinator of NANBIOSIS U10. [...]

30 Apr

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies. The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the [...]

02 Mar

NANBIOSIS Unit 10 of Drug Formulation participates in the European Project Position II

Nanobiocel, the CIBER-BNN – UPV-EHU group, led by José Luis Pedraz, Scientific Director of NANBIOSIS-ICTS U10 “Drug Formulation Unit” participates in the Position II European project, coordinated by Philips Electronics Nederland. The project, funded through the Horizon 2020 call with a global budget of more than 50 million euros, will be developed during three years [...]

23 Feb

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the [...]

25 Jan

Cryopreservation of stem cells

Scientific Reports of the Nature Publications Group has recently published the article ‘Cryopreservation of human mesenchymal stem cells in an allogeneic bioscaffold based on platelet rich plasma and synovial fluid’. This research is part of the doctoral thesis of Haritz Gurruchaga, belonging to the NanoBioCel group of CIBER-BBN and UPV / EHU, which is focused [...]

25 Jan

Therapeutic approaches with CRISPR for albinism

Preclinical Development of CRISPR- based non-viral therapeutic approaches in existing cellular and animal models of Albinism, (NanoCripsAlbino Therapy)  is a multidiciplinar project to study ways to bring genetic editing tools to target cells to develop therapeutic strategies that can be used to treatment. The project, participated by Lluís Montoliu (CIBERER) and José Luis Pedraz (CIBER-BBN) [...]

U10-Drug Formulation
Read More

U18. Nanotoxicology Unit

Ciber bbn

U18. Nanotoxicology Unit

  • Scientific Director: Prof. RamonMangues rmangues@santpau.cat
  • Scientific Coordinator: Mª Virtudes Céspedes  mcespedes@santpau.cat
  • Entities: Institut de Recerca. Hospital de la Santa Creu i Sant Pau & Institut de Recerca de Hospital Universitari Vall D’Hebron
  • Address: Hospital Santa Pau. c/Sant Antoni M. Claret, 167, 08025, Barcelona, Spain | Hospital Universitari Vall d’Hebron. Passeig Vall D’Hebron, 119-129, 08035, Barcelona, Spain
  • Phone: +34 935 537 918
  • Web: WEB

Vall-d´Hebrón SAN-PAU

Order request

Description

This Unit is located in the Hospital de la Santa Creu i Sant Pau, in Barcelona, and is coordinated by Dr. Ramón Mangues, PI of the Oncogenesis and Antitumor Drug Group. The main objective of the Nanotoxicology Unit is to assess the toxicity of new drugs, nanoparticles or nanotechnology-based biomaterials in in vitro and in vivo systems, with the goal of optimizing lead compounds and identifying those with the highest probability of success in the preclinical programme due to their greater safety and tolerability or reduced toxicity. The Unit has rooms equipped for cell culture, for cryopreservation of samples and cell lines, and for sample preparation and analysis and animal facilities for in vivo experimentation.

Equipment: The Unit has access to flow cytometers, sorters, confocal microscope and other equipment of the Platforms available at the Hospital Research Institute as well as housing facilities for small rodents (rat and mouse).

U18-Nanotoxicology Unit
Read More

U20. In Vivo Experimental Platform

Ciber bbn

U20. In Vivo Experimental Platform

U20. logo FVPP CIBBIM-Nanomedicina Vall d'HebronVall d´Hebrón_U20,U18

Order request

Description

Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.

This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.

News U20

11 Jun

NANBIOSIS Unit 20 expands its equipments and capabilities

NANBIOSIS U20- In Vivo Experimental Platform, led by Dr Simó Schwartz and Dr. Ibane Ibasolo, has recently added new equipment as a result of its participation in the project FICTS1420-20, selected by the MINECO for co-financing by the FEDER Program in ICTS 2014-2020. The new equipment is a Coagulometer (Diagnostica Stago STart® 4 Hemostasis Analyzer) used for measuring the  plasma coagulation time upon incubation with different stimulators (PT, APTT, Fibrinogen, D-dimer (quantitative), Thrombin time, Reptilase time etc.) the use o f this equipment will  allow the Unit to test the hemocompatibility of novel nanomedicines in development.[...]

05 Jun

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds. Also CSIC (The State Agency Superior Council of[...]

21 May

Mesenchymal stem cells or exosomes with fibrin glue mesh fixation modulates the inflammatory reaction in a murine model of incisional hernia

Javier García Casado, Scientific Director of NANBIOSIS U14, Cell Therapy Unit, and Francisco Miguel Sánchez Margallo, Scientific Director of  CCMIJU, are co-author of the publication “Fibrin glue mesh fixation combined with mesenchymal stem cells or exosomes modulates the inflammatory reaction in a murine model of incisional hernia” by Acta Biomaterialia. In vitro experiments were performed by the ICTS Nanbiosis (Unit 14. Cell therapy at CCMIJU). Exosomes characterization was performed by the ICTS Nanbiosis (Unit 6: Biomaterial processing and Nanostructuring Unit). In vivo experiments were performed by the ICTS Nanbiosis (Unit 22. Animal housing at CCMIJU). The study has demonstrated a[...]

11 May

Fabry disease awareness month, April

The Fabry International Network (FIN) association established the month of April as the “month of Fabry” to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry Disease is one of several dozen Lysosomal Storage Disorders that interfere with the body’s ability to break down specific fatty substances. It is a rare disease and because the rate of occurrence is less than 1 in 200,000, it is considered as one of the many “Orphan” diseases. It is more common in women, but it occurs with greater severity in men. Fabry disease is a metabolic[...]

07 May

The EVO-NANO project will allow testing the behavior of nanoparticles within a tumor

The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies)  within the Horizon 2020 program. The EVO-NANO project aims to develop a virtual simulator, called NanoDoc, which will allow testing the behavior of nanoparticles within a tumor and with other nanoparticles. It is a multidisciplinary project that will develop a consortium of European research centers with the aim of creating a platform available to everyone and at the forefront of Nanomedicine that facilitates the rapid development and testing of new treatments against cancer. “It will become an evolutiv[...]

07 May

Conference on Nanotoxicity, next May 24, Parc Scientific of Barcelona

NANBIOSIS is organizing a Conference on Nanotoxicity in collaboration with Nanomed Spain and Materplat, next May 24 in the Parc Scientific of Barcelona, to debate about the efect of nanotoxicity of nanoparticles and nanotechnologies in health. The increase of potential risks to health has created the new discipline of nanotoxicity, that is, the study of the toxicity produced by the effect of nanoparticles and nanomaterials. The objective of this day is to learn more about the lines that are being followed by researchers in the area of ​​nanotoxicity, the progress of different projects in this field, as well as existing[...]

10 Apr

Dr. Simó Schwartz Jr, appointed editor of Precision Nanomedicine magazine

The new magazine “Precision Nanomedicine” in its online version, is about to be issued. Dr. Simón Schwartz Jr, Scientific Director of NANBIOSIS U20 In Vivo Experimental Platform, is one of only two Spanish researchers who are part of the editorial board of the journal. The rest of publishers belong to the United States, Australia, Japan and Europe Precision Nanomedicine is a publication promoted by the European Society of Nanomedicine (ESNAM for its acronym in English), the European Nanomedicine Foundation and the Conference of Clinical Nanomedicine (Clinamen). It was born with the aim of bringing together the most important opinion leaders in this field, disseminating t[...]

14 Mar

A new polymeric nomedicin facilitates simultaneous pharmacological and gene silencing therapies

Simó Shwartz, Scientific Director of NANBIOSIS U20 In vivo Experimental Platform, has recently published an interesting article “Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized Pluronic® F127/Gelatin” issued by  Chemical Engineering Journal. The research group of Dr Schwartz has managed to create a micelle formed by a combination of polymers and gelatin that allows to transport effectively large quantities of both nucleic acids and drugs inside. The system also leads to the periphery a series of carboxylic groups that allow anchoring in a very easy way any type of directing molecule such as for example a peptide or[...]

U20-In Vivo Experimental Unit
Read More